首页> 外文期刊>British Journal of Radiology >Acute adverse reactions to iopromide vs iomeprol: A retrospective analysis of spontaneous reporting from a radiology department
【24h】

Acute adverse reactions to iopromide vs iomeprol: A retrospective analysis of spontaneous reporting from a radiology department

机译:碘普罗胺与碘美普尔的急性不良反应:放射科自发报告的回顾性分析

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To compare the safety of iopromide and iomeprol use in a hospital that switched fromthe former to the latter and found an apparent increase in the number (and a different profile) of adverse reactions reported for iomeprol, putting the safety of its use into question. Methods: This was a retrospective study of cases of acute reactions to iopromide and iomeprol reported in two successive time periods. Data from examinations using iopromide (62 539 CT scans and 10 348 urography scans) and iomeprol (34308 CT scans and 2846 urography scans) were obtained from the computer system of the hospital. Results: For each period, 154 cases of reactions were reported for iopromide and 86 for iomeprol, being severe in 10 (6.5%) patients for iopromide vs 17 (19.8%) patients for iomeprol; a statistically significant difference of <,0.003 was recorded. The most frequent adverse reactions (%/%) for iopromide/iomeprol were urticaria (29.1/17.2), pruritus (22.6/15.6), upper respiratory tract signs and symptoms (12.1/16.7), oedema (4.3/0), erythemas (3.4/5.0), nausea or vomiting (1.2/11.7) and chest pain (0/3.9) (<,0.0001 for the global comparison). The distribution of the reactions (%/%) by System Organ Class for iopromide/iomeprol was skin (56.7/41.1), respiratory (19.2/26.7), vascular (6.8/2.2), general (5.3/7.2), gastrointestinal (4.6/15.0) and others (7.4/7.9) (<,0.0002 for the global comparison). Conclusion: Adverse reactions were more severe for iomeprol. Skin and vascular reactions with no chest pain were more frequent for iopromide, whereas gastrointestinal reactions were more frequent for iomeprol. Advances in knowledge: Comparative studies of media contrast safety are scarce and summary information on product characteristics is insufficient. This study showed the differences in severity and profile of adverse reactions between iopromide and iomeprol.
机译:目的:比较在从前者改为后者的医院中使用碘普罗胺和艾美普尔的安全性,发现报告的艾美普尔不良反应数量(和不同特征)明显增加,这使使用它的安全性受到质疑。方法:这是一项回顾性研究,研究了连续两个时期报告的对碘普罗胺和碘美普尔的急性反应。使用碘普罗胺(62 539 CT扫描和10 348尿路造影扫描)和碘美普尔(34308 CT扫描和2846尿路造影扫描)的检查数据是从医院的计算机系统获得的。结果:每个时期内,碘普罗胺的反应报道为154例,艾美普尔的反应为86例,其中碘普罗米特的10例(6.5%)患者比较严重,艾美普罗的17例(19.8%)患者严重。记录的统计学差异<0.003。 iopromide / iomeprol最常见的不良反应(%/%)为荨麻疹(29.1 / 17.2),瘙痒(22.6 / 15.6),上呼吸道体征和症状(12.1 / 16.7),水肿(4.3 / 0),红斑( 3.4 / 5.0),恶心或呕吐(1.2 / 11.7)和胸痛(0 / 3.9)(全球比较,<0.0001)。按系统器官分类,对于碘丙丙胺/艾美普罗,反应的分布(%/%)是皮肤(56.7 / 41.1),呼吸道(19.2 / 26.7),血管(6.8 / 2.2),一般(5.3 / 7.2),胃肠道(4.6) /15.0)和其他(7.4 / 7.9)(全局比较<0.0002)。结论:iomeprol的不良反应更为严重。无胸痛的皮肤和血管反应对碘普罗胺更频繁,而胃肠道反应对艾美普利则更为频繁。知识的进步:缺乏媒体对比安全性的比较研究,并且关于产品特性的摘要信息不足。这项研究显示了碘普罗胺和艾美普尔之间不良反应的严重程度和分布情况的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号